Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Biomatics Capital, based in Seattle, Washington, is a venture capital firm focused on healthcare innovation. The firm supports companies at the intersection of genomics and digital data, with a particular emphasis on therapeutics and diagnostics. They have a notable investment history, including a significant role in Editas Medicine's funding and IPO.
This firm invests in seed to Series B stages, targeting sectors like digital health, medical technology, gene editing, and proteomics. Biomatics Capital seeks outlier companies with disruptive ideas that can transform existing healthcare markets.
Notable investments include Editas Medicine, which focuses on CRISPR-Cas9 gene editing technology. Biomatics Capital led a $120 million Series B round for Editas in 2015, contributing to their successful $94.4 million IPO in 2016.
Email info@biomaticscapital.com with your deck to pitch them directly.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.